

Date: 7<sup>th</sup> November 2024  
Ref: CORP 2024 - 197

Dear xxx

**Freedom of Information request: Treatment of Renal Cell Carcinoma (CORP 2024 – 197)**

Thank you for your request for information which the Trust received on 10<sup>th</sup> October 2024.

Your Request:

**Q1.** *How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):*

- *Avelumab + Axitinib*
- *Axinitib*
- *Cabozantinib*
- *Everolimus*
- *Lenvatinib + Everolimus*
- *Lenvatinib + Pembrolizumab*
- *Nivolumab monotherapy*
- *Nivolumab + Cabozantinib*
- *Nivolumab + Ipilimumab*
- *Pazopanib*
- *Pembrolizumab monotherapy*
- *Pembrolizumab + Axitinib*
- *Radiotherapy only*
- *Sunitinib*
- *Temsirolimus*
- *Tivozanib*
- *Other active systemic anti-cancer therapy*
- *Palliative care only*

**Q2.** *In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?*

**Q3.** *Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?*

Please find the Trust's response below:

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.

**Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):**

Regimen	Number of Distinct Patients
Pembrolizumab monotherapy	7
Avelumab + Axitinib	<6*
Nivolumab + Ipilimumab	<6*
Nivolumab monotherapy	30
Palliative care only	16
Pembrolizumab + Lenvatinib	21
Tivozanib	0
Axitinib	0
Cabozantinib	<6*
Everolimus	0
Lenvatinib + Everolimus	0
Nivolumab + Cabozantinib	0
Pazopanib	0
Pembrolizumab + Axitinib	0
Radiotherapy only	0
Sunitinib	0
Temsirolimus	0
Other active systemic anti-cancer therapy	<6*


Data shows number of unique patients treated with the above, as such some of these patients may have received more than one of these drugs/treatments

\*Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

**Q2. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?**

Velindre University NHS Trust is a nationally recognised specialist centre of excellence for the provision of non-surgical oncology including radiotherapy and chemotherapy; specialist palliative care; blood transfusion; specialist immunohaematology; antenatal blood testing reference work; and transplant immunology. The Trust provides a range of specialist non-surgical oncology services to approximately 1.5 million people of South-East Wales, and to the whole of Wales for some services, working in partnership with the hospitals managed by the Local Health Boards. The

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Welsh Blood Service collects processes and delivers blood and blood products to hospitals across Wales.

**Q3. Does you trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?**

The Trust is currently participating in one clinical trial for the treatment of renal cell carcinoma: RAMPART – 12 participants recruited.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

You should forward your complaint to:

Mr Ian Bevan via [FOI.VUNHST@wales.nhs.uk](mailto:FOI.VUNHST@wales.nhs.uk)  
Head of Information Governance  
Velindre University NHS Trust  
2 Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff, CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales  
2nd Floor Churchill House,  
Churchill Way,  
Cardiff, CF10 2HH  
Telephone: 0330 414 6421 / email: [wales@ico.org.uk](mailto:wales@ico.org.uk)

Yours sincerely

**Non Gwilym**  
**Interim Director of Corporate Governance**  
Velindre University NHS Trust  
2 Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.

